© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
December 29, 2020
The myeloma expert discussed the importance of sustained MRD negativity for patients with multiple myeloma treated with daratumumab (Darzalex).
December 23, 2020
The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.
December 05, 2020
Voorhees noted that despite challenges associated with the COVID-19 pandemic, emerging therapies offer hope for patients with multiple myeloma.
February 18, 2020
The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma.